NAPTER
Scheda del progetto
Dr. Giovanni Paolo Stola
Dr. Mattia Spedicati
Dr. Andrea Bezze
Dr. Daniele Testore
Dr. Martina Coletto
Prof. Clara Mattu
Dr. Noemi Giordano
Post-myocardial infarction ischemic heart disease is the leading cause of death worldwide, with no clinical therapies capable of restoring cardiac function. RNAs represent a promising therapeutic frotnier, but its clinical applications are limited due to the lack of safe release systems. The NAPTER project is developing a new platform of hybrid polymer nanoparticles for the safe and effective release of specific microRNAs to target cells, aiming to recover cardiac function by reprogramming fibroblasts in the fibrotic scar into cardiomyocytes. NAPTER nanoparticles, which are biocompatible and effective according to preliminary tests, are produced using a patented scalable method. The project includes dose-dependent efficacy analysis, the development of AI-based methods, scale-up production, de-risking tests, and the definition of an industrial development strategy, along with entrepreneurial training and investor engagement for the creation of a spin-off.
Contact:
Contact person
Valeria Chiono
Email
valeria.chiono@polito.it
Tel
+39 0110906920
+39 3273636923
The project aims to raise the Technology Level (TRL) from 4 to 5 by completing ''de-risking'' tests, including dose-dependent efficacy tests on transgenic mouse model, scale-up production of NP using microfluidic methods and the definition of preclinical tests according to GLP (Good Laboratory Practice). Another objectives is to implement an industrial development strategy through entrepreneurial training for the team and the definition of a business plan for the creation of a spin-off.
NAPTER introduces an innovative platform of hybrid polymeric nanoparticles, combining lipid components for effective encapsulation of miRNAs and polymeric components to enhance in vivo stability and allow targeted release to specific cells. This technology overcomes the limitations of standard lipid transfusers agents and lipid nanoparticles, offering a safe and functional solution for cell reprogramming in cardiac regenerative medicine applications.
NAPTER has the potential to revolutionise the treatment of post-infarction heart failure, improving patient quality of life and reducing the economic impact of cardiovascular diseases. Patients will benefit from an innovative therapy aimed at restoring cardiac function and enhancing quality of life. Physicians will have an advanced therapeutic solution to address post-infarction heart failure. Healthcare facilities will be able to offer cutting-edge treatment to patients and stand out from the competition.